In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Esperion Therapeutics Inc (NASDAQ: ESPR) closed at $0.98 down -0.93% from its previous closing price of $0.99. In other words, the price has decreased by -$0.93 from its previous closing price. On the day, 1.5 million shares were traded. ESPR stock price reached its highest trading level at $1.03 during the session, while it also had its lowest trading level at $0.9844.
Ratios:
For a deeper understanding of Esperion Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.81 and its Current Ratio is at 1.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 18, 2024, initiated with a Neutral rating and assigned the stock a target price of $4.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $8.
BofA Securities Downgraded its Neutral to Underperform on June 20, 2024, while the target price for the stock was maintained at $2.50.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 17 ’25 when Looker Benjamin sold 6,422 shares for $1.15 per share. The transaction valued at 7,398 led to the insider holds 401,241 shares of the business.
Koenig Sheldon L. sold 30,474 shares of ESPR for $33,796 on Jun 17 ’25. The President and CEO now owns 1,541,488 shares after completing the transaction at $1.11 per share. On Jun 17 ’25, another insider, Halladay Benjamin, who serves as the Chief Financial Officer of the company, sold 7,229 shares for $1.15 each. As a result, the insider received 8,328 and left with 474,473 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 195107104 and an Enterprise Value of 674477568. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.75. Its current Enterprise Value per Revenue stands at 2.598 whereas that against EBITDA is -16.898.
Stock Price History:
The Beta on a monthly basis for ESPR is 0.70, which has changed by -0.58119655 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, ESPR has reached a high of $3.94, while it has fallen to a 52-week low of $0.69. The 50-Day Moving Average of the stock is 1.47%, while the 200-Day Moving Average is calculated to be -43.08%.
Shares Statistics:
For the past three months, ESPR has traded an average of 5.17M shares per day and 2917970 over the past ten days. A total of 196.66M shares are outstanding, with a floating share count of 194.62M. Insiders hold about 1.80% of the company’s shares, while institutions hold 57.31% stake in the company. Shares short for ESPR as of 1749772800 were 24113664 with a Short Ratio of 4.66, compared to 1747267200 on 27945316. Therefore, it implies a Short% of Shares Outstanding of 24113664 and a Short% of Float of 12.2200005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
